Vernon Hills, IL November 3, 2008 - Applied NeuroSolutions, Inc. (OTC BB:APNS, www.appliedneurosolutions.com), a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer’s disease (AD), today announced the appointment of Edward A. Ogunro, Ph.D., a diagnostic and pharmaceutical industry veteran, to its Board of Directors.

Dr. Ogunro has had a long and distinguished career in both the healthcare industry and academia.  He recently retired from his position as Senior Vice President, R&D and Medical Affairs and Chief Scientific Officer at Hospira, Inc. (NYSE: HSP) where he was part of the executive management team that transitioned the company from a division of Abbott Laboratories to a successful stand-alone entity.

He joined Abbott Labs (NYSE : ABT) as a Research Biochemist in the Diagnostics Division and took on roles of increasing responsibility including Program Director for AxSym, one of the most successful analyzers in the diagnostic industry.  In addition, in his 20 plus years at Abbott Labs, Dr. Ogunro held senior leadership positions including Divisional Vice President, Immunodiagnostics and Chemistry in the Diagnostics Division and Corporate Vice President R&D, Medical and Regulatory Affairs in the Hospital Products Division. Previously, Dr. Ogunro pursued postdoctoral studies and served as an Assistant Professor at Northwestern University Medical School in Chicago.

Commenting on the appointment, Ellen R. Hoffing, APNS Chairman said, “I am delighted that Edward Ogunro has joined our Board as he brings significant hands on experience in the development and commercialization of numerous very successful diagnostic products and provides a unique perspective gained as a result of his notable science and technical background in the healthcare industry.  The appointment of Dr. Ogunro allows us to continue to build and hone the expertise of our Board of Directors to support the success of our development programs. Edward’s knowledge and experience will be invaluable as we continue building the APNS pipeline of Alzheimer’s disease diagnostics and therapeutics.”

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTC BB:APNS - News) is developing diagnostics and therapeutics to detect and treat Alzheimer's disease (AD) building on discoveries originating from the Albert Einstein College of Medicine.  Applied NeuroSolutions is in a collaboration with Eli Lilly and Company to develop novel therapeutic compounds to treat the progression of AD.  For its diagnostic pipeline, Applied NeuroSolutions is focused on both cerebrospinal fluid (CSF) and serum tests to detect AD at a very early stage.  The P-Tau 231 test now being offered for use in clinical trials can effectively differentiate AD patients from those with other neurological diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect AD. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be 30 million patients.  For more information, visit www.AppliedNeuroSolutions.com

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.AppliedNeuroSolutions.com, and review the company's filings with the Securities and Exchange Commission.

Contact:
Applied NeuroSolutions 847-573-8000
Ellen Hoffing, President, CEO
David Ellison, CFO